Orthocell has announced that it has recorded impressive sales growth across its product portfolio, with total revenue for FY24 of $6.72million – up 30.40% from the previous financial year, FY23.
Petra Capital has released research report, forecasting Orthocell’s potential to reach A$1.28 per share.
Orthocell has applied to the Therapeutic Good Administration (TGA) for Australian market approval for its SmrtGraft™ tendon repair device, in preparation for its introduction into the Australian tendon repair and regeneration market.
Orthocell has announced that results from the Remplir™ nerve regeneration clinical trial have been published in a high profile clinical journal.
Orthocell has announced that it has received a Research and Development (R&D) Tax Incentive refund of A$3,051,483 for the financial year 2022/2023.
Orthocell has today published its Quarterly Report for the period ended 31 March 2024.
Orthocell Managing Director, Paul Anderson, spoke with Jonathan Jackson at Proactive to provide an update on the Company’s market authorisation study for nerve repair device, Remplir™.
Orthocell has announced that it has successfully completed the first stage of the Remplir™ US 510(k) market authorisation nerve repair study. All surgical repairs of severed nerves were performed with no adverse events reported. This provides us with confidence that the final two stages, in which safety and effectiveness will be evaluated, will be consistent […]
Orthocell CEO Paul Anderson spoke with Proactive about the Company’s recent strategic placement of $3.5 million, adding prominent investors to the share register.
Orthocell has today announced that it has completed a Company-led Strategic Placement to raise $3.5 million.